MAY 28, 2014 06:00 AM PDT

The new role for HPV DNA testing: cobas HPV Test as a first-line cervical cancer screen

Speakers
  • Scientific Affairs Manager, Medical and Scientific Affairs, Roche Diagnostics
    Biography
      Dr. Julia Engstrom-Melnyk is a Scientific Affairs Manager within Medical and Scientific Affairs for Roche Diagnostics Corporation, supporting two geographic territories and serving as the scientific and clinical HPV subject matter expert for the U.S.  In these roles, she has collaborated with both North American and global colleagues on several high-profile projects and studies and has served as an invited speaker at both domestic and international conferences. Dr. Engstrom-Melnyk received her Ph.D. in Molecular Biology and Genetics from the University of Delaware, discovering and developing gene therapy approaches to treat genetically-inherited disorders.  As a Postdoctoral Fellow at Harvard Medical School/Beth Israel Deaconess Medical Center, her research explored signaling pathways following DNA damage and the biological processes of DNA repair.Dr. Julia Engstrom-Melnyk is a Scientific Affairs Manager within Medical and Scientific Affairs for Roche Diagnostics Corporation, supporting two geographic territories and serving as the scientific and clinical HPV subject matter expert for the U.S. In these roles, she has collaborated with both North American and global colleagues on several high-profile projects and studies and has served as an invited speaker at both domestic and international conferences. Dr. Engstrom-Melnyk received her Ph.D. in Molecular Biology and Genetics from the University of Delaware, discovering and developing gene therapy approaches to treat genetically-inherited disorders. As a Postdoctoral Fellow at Harvard Medical School/Beth Israel Deaconess Medical Center, her research explored signaling pathways following DNA damage and the biological processes of DNA repair.

    Abstract:

    For the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology -- if it is negative, women are rescreen in three years and if positive, are referred to follow-up examinations. Although this strategy has led to a tremendous reduction in the incidence of cervical cancer, some significant limitations exist. Cytology has low sensitivity for cervical cancer pre-cursors, has low reproducibility, and does not adequately assess long-term risk. HPV testing added to cytology as a co-test for women 30 years and older increases the sensitivity of cytology and addresses many of its limitation, but also significantly contributes to the complexity of management. Additionally, it does not address the women 25-29 who are still screened with cytology alone. In ATHENA, 28% of all CIN3+ lesions detected were in women 25-29 -- more high-grade disease was found in these 6,647 women than in the 22,006 women 40 years and older. Further, cytology-based screening, the only other option for women 25-29, was negative in more than 57% of these cases, suggesting that current screening with cytology is inadequate in identifying underlying CIN3+ lesions in this age group. This is highly relevant when assessing data from the National Cancer Institute's SEER Tumor Registry, which shows a sharp rise in the incidence of invasive cervical cancer between the ages of 25 and 34 years. Since the goal of cervical cancer screening is to prevent cervical cancer from developing, it important to identify high-grade cervical cancer precursors in women 25-29 years, so that the precursors can be treated prior to this up rise in cervical cancer incidence and cervical cancer may be prevented. As a solution, HPV DNA testing can be used as a first-line primary screen in women 25 and older to not only enhance screening sensitivity but also reduce the complexity of a co-test.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    Loading Comments...
    Show Resources